Skip Content
Page Banner Image


Triplet Therapeutics has developed the SHIELD HD natural history study for Huntington disease (HD), which recently enrolled its first patients. The study will include about 60 HD gene carriers – both pre-manifest and early manifest individuals – and is intended to inform future clinical trials.

If you’re not familiar with Triplet’s therapeutic approach, it’s different from other therapies currently entering the HD clinic, in that it targets a newly discovered set of modifiers for HD instead of the HTT gene. Operating “upstream” means that Triplet may be able to treat the disease very early — an approach that could preserve neuronal function and halt neurodegeneration.

The study is registered at (Note:  lists only the first open site, but there will be more – currently the plan is for 2 sites in Canada.)

You can see the full press release online here.

Status: Currently recruiting.

Study Type: Observational

Canadian Locations:


Location: North York General Hospital, Toronto
Status: Recruiting
Coordinator: Clare Gibbons
Phone: 416-756-6788

We support those facing huntington disease
 Latest Blog


Have questions? Send us an email at:



Stay in Touch!
Enter your email address below to receive occasional updates.

Newsletter Sign-up

Copyright © Huntington Society of Canada. All Rights Reserved. Charitable Registration Number 11896 5516 RR0001